HEALTHCARE creates added value for investors .

SUDA ’ s business model doesn ’ t involve sales and marketing , but instead revolves primarily around out-licensing to pharmaceutical companies around the world to complete the clinical developments to the extent required , as well as oversee the registration and commercialization of SUDA ’ s pipeline of sprays .

In these licensing agreements , SUDA seeks up-front payments for the license , milestone payments associated with the successful registration of the products , commercial milestones associated with hitting sales targets and royalties on sales .

“ Ultimately we will create value through the up-front and milestone payments , and the sustainable income that comes with royalty flows ,” said Woolf . “ In our codevelopment collaborations where companies are coming to us , they will pay for us to do the formulation work , and if it was formulated in our lab , we will seek to have a royalty income stream from it .”

SUDA also works with manufacturers , such as IDT in Australia , who operate to the standards of good manufacturing

– Chief Business Officer Nick Woolf

www . sudaltd . com . au 51